Efficacy of Vitamin D Supplementation on Adult Patients with Non-Alcoholic Fatty Liver Disease: A Single Centre Experience
Gastroenterology and Hepatology from Bed to Bench,
26 January 2021
Background and Aim
The association between vitamin D level and NAFLD has not been determined yet. The aim of this study was to determine the efficacy of 6-months intramuscular vitamin D supplementation in improving the liver parameters in adult patients with NAFLD.
A single-blinded non-randomized controlled trial was conducted in 80 NAFLD patients assigned to receive a monthly single intramuscular dose of 200,000 IU cholecalciferol/vitamin D3 (n=40), or placebo (n = 40) for six months. Transient elastography for measurement of controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), as well as fibrosis 4 score (FIB4) and NAFLD fibrosis score (NFS) were performed.
The mean serum 25(OH)D was significantly increased after six months of vitamin D treatment (16.31±10.23 Vs 39.37 ±11.99 ng/ml). In the vitamin D group, most of vitamin D deficiency patients (70% deficiency, 10% insufficiency, and 20% sufficiency) had changed to be sufficient (7.5% deficiency, 5% insufficiency, and 87.5% sufficiency). On the other hand, the values of CAP (311.9±42.2dB/m) and LSM (6.8±2 kPa) had significantly reduced after six months of supplementation (287.0 ±44.3dB/m and 6.1 ±1.1 kPa, respectively) with significantly higher mean CAP and LSM change from baseline in vitamin D group compared to the placebo group. Furthermore, the ALT and AST levels were significantly improved in Vitamin D group compared to the placebo group (P<0.05). Multivariate regression analysis showed that lower serum 25(OH)D level was the only significant predictor for NAFLD [OR=0.89, p=0.001) in this study.
A monthly single intramuscular dose of 200,000 IU cholecalciferol is effective in improving the laboratory and fibroscan parameters of the liver disease in NAFLD patients, which confirm the signiﬁcant relationship between vitamin D deficiency and the risk of NAFLD.
Keywords: NAFLD, vitamin D, CAP, and LSM
- vitamin D
- and LSM
M. Eliades, “Vitamin D: A new player in non-alcoholic fatty liver disease?,” World J. Gastroenterol., vol. 21, no. 6, p. 1718, 2015, doi: 10.3748/wjg.v21.i6.1718.
X. Wang, W. Li, Y. Zhang, Y. Yang, and G. Qin, “Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.,” Int. J. Clin. Exp. Med., vol. 8, no. 10, pp. 17221–34, 2015.
Z. M. Younossi et al., “Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis,” Hepatology. 2018, doi: 10.1002/hep.29724.
S. G. Sheth, F. D. Gordon, and S. Chopra, “Nonalcoholic steatohepatitis.,” Ann. Intern. Med., vol. 126, no. 2, pp. 137–45, Jan. 1997, doi: 10.7326/0003-4819-126-2-199701150-00008.
S. Zúñiga, D. Firrincieli, C. Housset, and N. Chignard, “Vitamin D and the vitamin D receptor in liver pathophysiology,” Clin. Res. Hepatol. Gastroenterol., vol. 35, no. 4, pp. 295–302, Apr. 2011, doi: 10.1016/j.clinre.2011.02.003.
E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism, vol. 65, no. 8, pp. 1038–1048, Aug. 2016, doi: 10.1016/j.metabol.2015.12.012.
Z. M. Younossi et al., “Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis,” Hepatology. 2018, doi: 10.1002/hep.29721.
P. Angulo, “Obesity and Nonalcoholic Fatty Liver Disease,” Nutr. Rev., vol. 65, pp. S57–S63, Jun. 2008, doi: 10.1111/j.1753-4887.2007.tb00329.x.
N. Sharifi, R. Amani, E. Hajiani, and B. Cheraghian, “Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial,” Endocrine, vol. 47, no. 1, pp. 70–80, Sep. 2014, doi: 10.1007/s12020-014-0336-5.
H. Lorvand Amiri, S. Agah, S. N. Mousavi, A. F. Hosseini, and F. Shidfar, “Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.,” Arch. Iran. Med., vol. 19, no. 9, pp. 631–8, Sep. 2016, doi: 0161909/AIM.006.
I. Barchetta et al., “No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial,” BMC Med., vol. 14, no. 1, p. 92, Dec. 2016, doi: 10.1186/s12916-016-0638-y.
M. Foroughi, Z. Maghsoudi, and G. Askari, “The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD),” Iran. J. Nurs. Midwifery Res., vol. 21, no. 1, p. 100, 2016, doi: 10.4103/1735-9066.174759.
S. Abramovitch et al., “Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats,” Gut, vol. 60, no. 12, pp. 1728–1737, Dec. 2011, doi: 10.1136/gut.2010.234666.
Q. G. Zhou, F. F. Hou, Z. J. Guo, M. Liang, G. B. Wang, and X. Zhang, “1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells,” Diabetes. Metab. Res. Rev., vol. 24, no. 6, pp. 459–464, Sep. 2008, doi: 10.1002/dmrr.873.
C. Konstantakis, “Vitamin D deficiency in patients with liver cirrhosis,” Ann. Gastroenterol., 2016, doi: 10.20524/aog.2016.0037.
S. Abramovitch et al., “Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats.,” Gut, 2014, doi: 10.1136/gutjnl-2014-308175.
S. Abramovitch et al., “Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats,” Gut, 2011, doi: 10.1136/gut.2010.234666.
S. Liangpunsakul and N. Chalasani, “Serum Vitamin D Concentrations and Unexplained Elevation in ALT Among US Adults,” Dig. Dis. Sci., vol. 56, no. 7, pp. 2124–2129, Jul. 2011, doi: 10.1007/s10620-011-1707-x.
M. F. Holick, “High prevalence of vitamin D inadequacy and implications for health.,” Mayo Clin. Proc., vol. 81, no. 3, pp. 353–73, Mar. 2006, doi: 10.4065/81.3.353.
H. A. Bischoff-Ferrari, E. Giovannucci, W. C. Willett, T. Dietrich, and B. Dawson-Hughes, “Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.,” Am. J. Clin. Nutr., vol. 84, no. 1, pp. 18–28, Jul. 2006, doi: 10.1093/ajcn/84.1.18.
B. Dawson-Hughes, R. P. Heaney, M. F. Holick, P. Lips, P. J. Meunier, and R. Vieth, “Estimates of optimal vitamin D status.,” Osteoporos. Int., vol. 16, no. 7, pp. 713–6, Jul. 2005, doi: 10.1007/s00198-005-1867-7.
P. Angulo et al., “The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, vol. 45, no. 4, pp. 846–854, Apr. 2007, doi: 10.1002/hep.21496.
R. K. Sterling et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, Jun. 2006, doi: 10.1002/hep.21178.
M. M. Yousif, A. M. E. M. Sadek, H. A. Farrag, F. O. Selim, E. F. Hamed, and R. I. Salama, “Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis,” Intern. Emerg. Med., vol. 14, no. 5, pp. 753–761, Aug. 2019, doi: 10.1007/s11739-019-02042-2.
J. Arteh, S. Narra, and S. Nair, “Prevalence of Vitamin D Deficiency in Chronic Liver Disease,” Dig. Dis. Sci., vol. 55, no. 9, pp. 2624–2628, Sep. 2010, doi: 10.1007/s10620-009-1069-9.
M. T. Kitson and S. K. Roberts, “D-livering the message: The importance of vitamin D status in chronic liver disease,” J. Hepatol., vol. 57, no. 4, pp. 897–909, Oct. 2012, doi: 10.1016/j.jhep.2012.04.033.
C. M. Lange et al., “Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy,” J. Hepatol., vol. 54, no. 5, pp. 887–893, May 2011, doi: 10.1016/j.jhep.2010.08.036.
C. D. Byrne and G. Targher, “NAFLD: A multisystem disease,” J. Hepatol., vol. 62, no. 1, pp. S47–S64, Apr. 2015, doi: 10.1016/j.jhep.2014.12.012.
G. Xiao, S. Zhu, X. Xiao, L. Yan, J. Yang, and G. Wu, “Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis,” Hepatology, vol. 66, no. 5, pp. 1486–1501, Nov. 2017, doi: 10.1002/hep.29302.
A. Vallet-Pichard et al., “FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest,” Hepatology, vol. 46, no. 1, pp. 32–36, Jul. 2007, doi: 10.1002/hep.21669.
L. Pacifico, J. F. Osborn, E. Bonci, P. Pierimarchi, and C. Chiesa, “Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables,” Mini-Reviews Med. Chem., vol. 19, no. 4, pp. 310–332, Jan. 2019, doi: 10.2174/1389557518666181025153712.
M. Hariri and S. Zohdi, “Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials,” Int. J. Prev. Med., vol. 10, no. 1, p. 14, 2019, doi: 10.4103/ijpvm.IJPVM_499_17.
M. Eliades et al., “Meta-analysis: vitamin D and non-alcoholic fatty liver disease,” Aliment. Pharmacol. Ther., vol. 38, no. 3, pp. 246–254, Aug. 2013, doi: 10.1111/apt.12377.
G. Targher et al., “Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease,” Nutr. Metab. Cardiovasc. Dis., vol. 17, no. 7, pp. 517–524, Sep. 2007, doi: 10.1016/j.numecd.2006.04.002.
I. Barchetta et al., “Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes,” BMC Med., vol. 9, no. 1, p. 85, Dec. 2011, doi: 10.1186/1741-7015-9-85.
M. Manco, P. Ciampalini, and V. Nobili, “Low levels of 25-hydroxyvitamin D3 in children with biopsy-proven nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 6, pp. 2229–2229, Jun. 2010, doi: 10.1002/hep.23724.
- Abstract Viewed: 0 times